Varian Executive and Leadership Team

Faisal Siddiqui, the Vice President and Chief Operating Officer - Processes at Varian, directs the internal operational frameworks that support the manufacturing of advanced radiotherapy and radiosurgery equipment. By optimizing supply chain logistics and production workflows, the Chief Operating Officer - Processes ensures that high-precision medical devices reach clinical facilities with maximum efficiency. Faisal Siddiqui monitors cross-functional performance metrics to maintain rigorous quality standards across all manufacturing sites. This leadership role involves streamlining internal business processes to reduce lead times for critical cancer treatment hardware. Through the implementation of lean manufacturing principles, the Chief Operating Officer - Processes drives significant improvements in operational throughput. By aligning internal resource allocation with global demand, Siddiqui secures the necessary infrastructure to support the company's mission of expanding access to life-saving medical technology while maintaining strict regulatory compliance and operational excellence.

Sasa Mutic, the President, Radiation Oncology Solutions at Varian, architects the strategic vision for the company's core radiotherapy and radiosurgery product lines. Overseeing the development of software and hardware platforms, the President, Radiation Oncology Solutions ensures that clinical teams possess the most advanced tools for precise cancer treatment. Sasa Mutic manages the integration of digital health solutions into existing oncology workflows to enhance diagnostic accuracy and treatment planning. This leadership role involves collaborating with global research institutions to pioneer new methods in brachytherapy and external beam radiation. By focusing on technological innovation, the President, Radiation Oncology Solutions drives the evolution of patient-centered care models. Mutic maintains a strong focus on market expansion, ensuring that these sophisticated oncology solutions meet the diverse needs of healthcare providers worldwide. Ultimately, Mutic secures the company's position as a leader in the global oncology technology sector.

Stephen Jamison, the President, Proton Solutions at Varian, directs the development and deployment of advanced proton therapy systems. By overseeing the engineering and installation of these complex treatment centers, the President, Proton Solutions ensures that healthcare facilities can deliver highly precise radiation doses to tumors while sparing healthy tissue. Stephen Jamison manages the strategic expansion of proton therapy capabilities across major global markets, focusing on increasing accessibility for patients with complex cancer diagnoses. This leadership role involves coordinating with hospital administrators and clinical physicists to optimize the performance of proton therapy infrastructure. By driving innovation in beam delivery technology, the President, Proton Solutions enhances the efficacy of cancer treatment protocols. Jamison maintains a focus on operational reliability and long-term system performance, ensuring that these high-value assets provide consistent clinical value to providers and patients alike throughout the entire lifecycle of the equipment.

Andrew Shogan, the President, Multi-Disciplinary Oncology at Varian, architects the strategy for integrated care solutions that span multiple oncology specialties. By focusing on the convergence of software, hardware, and data analytics, the President, Multi-Disciplinary Oncology ensures that clinical teams can manage the entire patient journey from diagnosis to survivorship. Andrew Shogan oversees the development of platforms that facilitate seamless communication between different oncology departments, improving coordination and treatment efficiency. This leadership role involves identifying opportunities for cross-platform integration to provide a holistic view of patient health. By driving the adoption of comprehensive oncology software, the President, Multi-Disciplinary Oncology supports the company's goal of transforming cancer care through digital connectivity. Shogan maintains a focus on market-wide impact, ensuring that these multi-disciplinary solutions address the complex challenges faced by modern cancer centers, ultimately improving the quality and consistency of care delivered to patients globally.

David Hahn, the Varian Interventional Solutions Vice President & Chief Medical Officer at Varian, directs the clinical strategy for interventional oncology products. By bridging the gap between medical research and product development, the Varian Interventional Solutions Vice President & Chief Medical Officer ensures that new devices address unmet needs in minimally invasive cancer procedures. David Hahn oversees clinical trials and evidence generation to validate the efficacy of interventional hardware in diverse patient populations. This leadership role involves working closely with the engineering teams to refine device design based on real-world clinical feedback. By fostering partnerships with leading interventional radiologists, the Varian Interventional Solutions Vice President & Chief Medical Officer drives the adoption of advanced treatment techniques. Hahn maintains a focus on clinical safety and performance, ensuring that all interventional solutions adhere to the highest standards of medical practice while supporting the company's broader growth objectives.

Dee Khuntia, the Senior Vice President, Medical Affairs & Chief Medical Officer at Varian, leads the global medical strategy and clinical education initiatives. By providing expert guidance on the clinical application of radiotherapy and proton therapy, the Senior Vice President, Medical Affairs & Chief Medical Officer ensures that healthcare providers receive comprehensive support for complex treatment scenarios. Dee Khuntia manages relationships with global medical societies and regulatory bodies to advocate for advancements in cancer care standards. This leadership role involves overseeing the dissemination of clinical data and research findings to the broader medical community. By championing evidence-based medicine, the Senior Vice President, Medical Affairs & Chief Medical Officer drives the integration of new technologies into standard clinical practice. Khuntia maintains a focus on patient safety and clinical outcomes, ensuring that the company's medical strategy remains aligned with the evolving needs of oncologists and patients across international markets.